Methylenedioxybenzylamphetamine
Methylenedioxybenzylamphetamine (MDBA) is a psychoactive drug and a member of the phenethylamine and amphetamine chemical classes. It is known for its entactogenic effects.
Chemistry[edit]
Methylenedioxybenzylamphetamine is a chemical compound with the molecular formula C11H15NO2. It belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
Pharmacology[edit]
The pharmacological action of MDBA is similar to that of other psychoactive drugs. It acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). This means it increases the levels of these neurotransmitters in the brain by inhibiting their reuptake into the presynaptic neuron, leading to an increase in the extracellular concentrations of these neurotransmitters and therefore an increase in neurotransmission.
Effects[edit]
The effects of MDBA can vary greatly depending on the dose, the user's individual physiology, and the environment in which it's used. Common effects include feelings of openness, euphoria, empathy, love, and increased self-awareness. These effects can be accompanied by side effects such as jaw clenching, lack of appetite, and insomnia.
Risks[edit]
Like other psychoactive substances, MDBA carries risks. These can include dehydration, hyperthermia, bruxism, insomnia, and in rare cases, serotonin syndrome. Long-term use can lead to drug dependence and severe withdrawal symptoms.
Legal Status[edit]
The legal status of MDBA varies by country. In many countries, it is classified as a controlled substance, making its manufacture, distribution, or use without a license illegal.
See Also[edit]
Methylenedioxybenzylamphetamine[edit]
-
Methylenedioxybenzylamphetamine structure
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
